of glutamate’s role in the pathophysiology and treatment of mood disorders and the recent US FDA approval of ketamine for treatment-resistant depression. Riluzole has already been identified as a potential antidepressant treatment, with support for its antidepressant properties found in rodent models31 and small clinical studies. However, larger scale clinical trials have not provided clear evidence to support its efficacy. These enrichments, from hypothesis-free association with depression, show converging independent evidence from genetics of existing pharmacological targets based on underlying biological mechanisms.
